Core Insights - A leading pharmaceutical stock is experiencing a surge due to a potential deal with the Trump administration, which involves reducing the prices of weight-loss drugs in exchange for Medicare coverage [1] - President Trump is exerting pressure to lower prices of popular obesity drugs as part of the "most-favored-nation" pricing model [1] Company Performance - Eli Lilly & Co. (NYSE: LLY), a competitor in the weight-loss drug market, saw its Momentum score in Benzinga's Edge Rankings increase significantly from 20.58 to 53.23 within a week, indicating strong stock performance [4] - The surge in Eli Lilly's stock is attributed to better-than-expected third-quarter results, where the company exceeded estimates on both revenue and earnings, and raised its full-year guidance [4] Stock Movement - The stock of Eli Lilly surged by 2.09% on a specific Wednesday, closing at $925.81, marking a 14-month high following the news of the potential deal with the White House [5] - Eli Lilly's stock scores highly on Momentum, Growth, and Quality in Benzinga's Edge Stock Rankings, reflecting a favorable price trend across short, medium, and long-term periods [6]